Prevention of Heart Disease: Is LDL Reduction the Outcome of Choice? No, There Is More

Value in Health

Volumn 1, Issue 2, 1998, Pages 120-124

  Shepherd, J ^a,c   Park, J S ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013520053     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.120120.x     Document Type: Conference Paper

References (6)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
2. Buchwald II, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). New Engl J Med 1990;323:946-55.
3. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. Circulation 1991;83(1):357-63.
4. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990;121:293-8.
5. Abbott RD, McGee D. The Framingham Study, Section 37: the probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. NIH Publication No. 87-2284, 1987.
6. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on chemical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.